Loading...
Factors associated with late recurrence after completion of 5-year adjuvant tamoxifen in estrogen receptor positive breast cancer
BACKGROUND: Recent large trials have shown the survival benefits of 10-year use of tamoxifen by reducing late recurrence compared with 5-year therapy in estrogen receptor(ER)-positive breast cancer. We tried to identify clinical factors associated with the late recurrence. METHODS: We reviewed our d...
Na minha lista:
| Udgivet i: | BMC Cancer |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
BioMed Central
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4937609/ https://ncbi.nlm.nih.gov/pubmed/27388210 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12885-016-2423-x |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|